Intellia Therapeutics, a biotech company, is in Cathie Wood’s portfolio and has a high Wall Street price target. Despite a setback, its gene-editing technology has potential. The company focuses on rare diseases, with Lonvo-z in a phase 3 clinical trial for hereditary angioedema. Nex-z, for ATTR amyloidosis, faces safety concerns, leading to a stock drop. Sales projections are optimistic, but investing in clinical-stage biotech carries risks. Consider cautiously before buying shares.

Read more at Yahoo Finance: Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%